“Arriving at the intersection of effective BPH treatment, patient priorities and available technology can be a daunting task,” said Mr. Olly Kayes, MD, Honorary Senior Lecturer at the University of ...

WAYNE, Pa., July 09, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) today announced that the largest U.S. healthcare claims and utilization analysis for benign prostatic hyperplasia (BPH) ...

Rates of surgical retreatment, alongside patient experience factors such as complications and adverse events (AEs), are important considerations when patients and their providers assess BPH therapies.

NeoTract, a wholly owned subsidiary of Teleflex Incorporated focused on addressing unmet needs in the field of urology, today announced the presentation of new clinical data at the World Congress of ...

NeoTract, a wholly owned subsidiary of Teleflex Incorporated focused on addressing unmet needs in the field of urology, today announced the results of an independent analysis measuring costs and ...

Dr. Irina Jaeger, director of urology at University Hospitals Richmond Medical Center, is making UroLift treatment for benign prostatic hypertrophy, or BPH, available in the area for the first time.

PLEASANTON, Calif.--(BUSINESS WIRE)--NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced the presentation ...

The committee concluded that UroLift is clinically effective, with sustained relief of lower urinary tract symptoms up to 5 years after treatment. It is implanted using a minimally invasive procedure.

For patients with benign prostatic hyperplasia (BPH), there are several options when to comes to surgical treatment. A comparison of real-world outcomes reveals significant differences in ...

This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of The ...